Nucletron gets FDA OK for OncoSmart Intracavitary

AuntMinnie.com staff writers
Apr 17, 2005

Radiotherapy provider Nucletron has received Food and Drug Administration 510(k) clearance for its OncoSmart Intracavitary applicator set.

The OncoSmart Intracavitary applicator is used for preoperative endorectal high-dose rate (HDR) and pulsed-dose rate (PDR) brachytherapy, according to the Veenendaal, Netherlands-based vendor.

By AuntMinnie.com staff writers
April 18, 2005

Related Reading

Nucletron installs Simulix simulator, March 9, 2005

Nucletron appoints de Groot, February 2, 2005

Nucletron showcases new products at ASTRO, October 4, 2004

Nucletron previews new Oncentra module, August 17, 2004

MDS Nordion, Nucletron partner, June 29, 2004

Copyright © 2005 AuntMinnie.com

Latest in Radiation Oncology/Therapy
Chatgpt
AI chatbots deemed ‘empathetic’ to cancer patients
May 16, 2024
Us Flag
ASTRO applauds new legislation on radiation therapy payments
May 15, 2024
Chat Gpt Artificial Intelligence Ai Head
ChatGPT-4 not reliable in cancer patient messaging
April 25, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
The rise of theranostics: Part 2 -- Moving into communities
April 4, 2024
Related Stories
Reuterslogo
Radiation Oncology/Therapy
Lower radiation dose saves hearing in acoustic neuromas
More in Radiation Oncology/Therapy
AI chatbots deemed ‘empathetic’ to cancer patients
By Will Morton
AI chatbots can generate high-quality, empathetic, and readable responses to cancer patients' questions compared with physicians.
May 16, 2024
Chatgpt
ASTRO applauds new legislation on radiation therapy payments
By AuntMinnie.com staff writers
The American Society for Radiation Oncology (ASTRO) applauded the introduction of legislation in Congress on May 15 that could radically change the way Medicare pays for radiation therapy.
May 15, 2024
Us Flag
ChatGPT-4 not reliable in cancer patient messaging
By Amerigo Allegretto
ChatGPT-4 is not a reliable source for answering patients’ questions regarding cancer and needs physician monitoring.
April 25, 2024
Chat Gpt Artificial Intelligence Ai Head
The rise of theranostics: Part 2 -- Moving into communities
By Liz Carey
In part 2 of The Rise of theranostics series, experts weigh in on getting started in prostate cancer theranostics as some private urology, radiation oncology practices, and radiologist groups begin building their abilities.
April 4, 2024
Theranostics with Thomas Hope, MD, University of California, San Francisco (UCSF)
The rise of theranostics: Part 1 -- Gaining momentum
By Liz Carey
FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.
March 26, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
Researcher outlines radiation oncology workforce challenges
By Amerigo Allegretto
Arya Amini, MD, spoke with AuntMinnie.com about a paper he co-authored that outlines workforce challenges being faced by radiation oncologists.
February 23, 2024
Screenshot (1076)
PET/CT radiomics predicts outcomes in women with cervical cancer
By Will Morton
A radiomics nomogram based on F-18 FDG-PET/CT imaging could help clinicians assess long-term outcomes in women undergoing treatment for locally advanced cervical cancer.
February 2, 2024
Representative example of tumor segmentation of radiomics regions of interest (ROI) on axial, coronal, and sagittal PET/CT imaging.
PSMA-PET helps plan treatment in men with relapsed prostate cancer
By Will Morton
PSMA-PET led to management changes in one-third of men receiving salvage radiotherapy for prostate cancer that recurred after radical prostatectomy.
January 31, 2024
Prostate Cancer
FAPI-PET shows promise in head and neck cancer patients
By Will Morton
In a comparative imaging trial, FAPI-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer.
January 26, 2024
PET/CT and MR images of a 72-year-old woman. (A) F-18 FDG-PET images (left and top) and PET/CT images (bottom) shown in coronal, sagittal, and axial views (from left to right), demonstrated a metastatic lymph node of the right neck with intensive metabolic activity (black arrow, SUVmax, 30.1) but presented no evidence for primary tumor. (B) Ga-68 FAPI-PET images (top and right) and PET/CT images (bottom), shown in axial, sagittal, and coronal views (from left to right), also detected metastatic lymph node with high Ga-68 FAPI tracer activity (black arrow, SUVmax, 16.3). There was intensive uptake of Ga-68 FAPI in palate (red arrow, SUVmax, 11.3). (C) T1-weighted, T2-weighted, and contrast-enhanced T1-weighted MRI also presented no evidence for primary tumor. Subsequent surgery confirmed mucoepidermoid carcinoma of palate. Image courtesy of the Journal of Nuclear Medicine.
TerraPower distributes first shipments of Ac-225
By AuntMinnie.com staff writers
TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials.
January 24, 2024
Isotopes1
FAPI-PET outperforms FDG-PET in diagnosing pancreatic cancer
By Will Morton
F-18 FAPI-PET/CT is superior to F-18 FDG-PET/CT for diagnosing and staging patients with pancreatic cancer.
January 5, 2024
Typical PET (top), PET/CT (middle), and CT and MR (bottom) images of primary tumor obtained using both radiotracers in representative patients (A and B). Tumor is marked by arrows. DWI = diffusion-weighted imaging. Image courtesy of the Journal of Nuclear Medicine.
PET/CT scans ‘crucial’ in patients with NK/T-cell lymphoma
By Will Morton
PET/CT has significant advantages over conventional methods for lesion detection and staging in patients with natural killer/T-cell lymphoma.
December 22, 2023
A 50-year-old man with recently diagnosed nasal-type NK/T-cell lymphoma underwent an F-18 FDG-PET/CT scan (A–D) for initial staging. Maximum-intensity-projection image (A) shows hypermetabolic lesions in both ethmoid sinus (thin arrow), both cervical lymphatic chains (arrowhead), left upper lung (thick arrow), liver, and spleen. Transaxial images show an F-18 FDG-avid mass in both ethmoid sinus (B). The scan shows intense F-18 FDG radiotracer uptake in left upper lung and uptake in the liver and spleen (CT showed no lesions), suggesting malignancy (C–D). Finally, after the PET/CT scan was done, the patient’s staging was changed from II to IV.
Page 1 of 461
Next Page